Vivos Therapeutics (NASDAQ:VVOS) is a medical technology company. It focuses on developing and marketing treatments for patients with sleep-disordered breathing, including obstructive sleep apnea (OSA). The company's business model centers on providing its therapeutic solutions through a network of trained medical and dental providers, including affiliated sleep centers.
On April 17, 2026, analyst firm H.C. Wainwright lowered its price target for Vivos Therapeutics to $2.50. This is a significant reduction from its previous target of $7.00. At the time of this adjustment, the company's stock was trading at a price of $1.01 per share.
This adjustment comes as the company shifts its strategy. As highlighted by defenseworld.net, Vivos Therapeutics is now focusing on a medical provider-focused model, a change driven by its June 2025 acquisition of the Sleep Center of Nevada. This new approach is central to its growth plans for 2026.
The strategy shows an impact on financial results. As highlighted by GlobeNewswire, full-year 2025 revenue for Vivos Therapeutics grew 16% to $17.50 million, up from $15.00 million in 2024. This increase is mainly due to a $4.80 million rise in sleep testing services and $2.20 million in revenue from patient treatments.
Despite revenue growth, the stock trades at $1.00, with a 52-week range between $0.96 and $7.95. The company has a market capitalization of about $5.89 million. Market capitalization is the total market value of a company's outstanding shares, found by multiplying the share price by the total number of shares.
